HBM Holdings (HKG:2142) said its U.S. partner, Spruce Biosciences, plans to list a newly established subsidiary focused on developing its experimental drug CRHX-101 on Nasdaq in the first half of 2027.
Spruce Biosciences has separated the CRHX-101 program into Adrenyx Biosciences, a wholly owned subsidiary, according to a Wednesday Hong Kong bourse filing. HBM expects to hold equity interests in both companies.
CRHX-101 is an experimental monoclonal antibody being developed to treat classic congenital adrenal hyperplasia. Adrenyx intends to submit an investigational new drug application to the U.S. Food and Drug Administration and begin clinical development thereafter.
Comments